Biotek-snakken — August 2021
-
Orphazyme H1 Net Loss Bigger Than Expected; Operating Loss Outlook
Unchanged https://www.proinvestor.com/investornyt/698583/orphazyme-h1-net-loss-bigger-than-expected-operating-loss-outlook-unchanged -
-
Bioshare: Tak for dit input.. Kassebeholdningen rækker til H2 2023, så det ligner de kan klare sig gennem frem til godkendelse uden kapitaludvidelse. Overvejer lige om jeg skal tage en mere kortsigtet position forud for FDA dialog. Men ellers bliver den på watch-listen indtil videre.
-
SK Bioscience, GSK Initiate Phase 3 Trial Of COVID-19 Vaccine Candidate https://www.proinvestor.com/investornyt/698604/sk-bioscience-gsk-initiate-phase-3-trial-of-covid-19-vaccine-candidate
-
-
Håbe 2022 bliver året hvor vi for alvor kommer til at se salget og indtjeningen øge markant. Nu har Photocure efterhånden lagt fundamentet i de fleste af verdens vigtigste markedet. Det bliver jo også utroligt spændende at se hvad som kommer til at ske med udviklingen af Cevira og salget af Cysview i Kina.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind